Tablets with high active ingredient content of omega-3 fatty acid amino acid salts

1. A tablet, comprising:

eicosapentaenoic acid combined with a first basic amino acid as an EPA salt;

docosahexaenoic acid combined with a second basic amino acid as a DHA salt;

a total amount of 20 wt. % or less, based on a total tablet weight, of a binder and/or a structure-forming substance selected from the group consisting of polyvinylpyrrolidone, starch, lactose, microcrystalline cellulose, calcium sulfate, mannitol, calcium phosphate, and a mixture thereof,

wherein the EPA and DHA salts are present as a mixture in powder form, and

wherein a sum of the eicosapentaenoic acid and the docosahexaenoic acid in the tablet is 40 wt. % or more, based on the total tablet weight and measured in free acid form.

2. The tablet of claim 1 , comprising, based on the total tablet weight, a total amount of no more than 10 wt. % of the binder and/or the structure-forming substance.

3. The tablet of claim 1 , wherein omega-3 fatty acids present in the tablet consist essentially of eicosapentaenoic acid and docosahexaenoic acid.

4. The tablet of claim 1 , wherein the first and second basic amino acid are independently selected from the group consisting of lysine, arginine, ornithine, and a mixture thereof.

5. The tablet of claim 1 , comprising the eicosapentaenoic acid and the docosahexaenoic acid in the tablet is 50 wt. % or more, based on the total tablet weight and measured in free acid form.

6. A method of preparing the tablet of claim 1 , the method comprising:

compressing the EPA salt and the DHA salt, optionally together with the binder and/or the structure-forming substance.

7. The method of claim 6 , comprising:

compacting the EPA salt and the DHA salt prior to the compressing.

8. The method of claim 6 , comprising:

granulating the EPA salt and the DHA salt with a solvent or a solvent mixture prior to the compressing.

9. The method of claim 6 , comprising:

precipitating the EPA salt and the DHA salt from an aqueous or alcoholic aqueous solution.

10. The method of claim 6 , comprising:

spray-drying of an aqueous or alcoholic aqueous solution of the first and second basic amino acid, the eicosapentaenoic acid, and the docosahexaenoic acid to obtain the EPA salt and the DHA salt.

11. A food supplement or a pharmaceutical product, comprising:

the tablet of claim 1 .

12. The method of claim 7 , comprising:

granulating the EPA salt and the DHA salt with a solvent or a solvent mixture prior to the compacting.

13. The tablet of claim 1 , comprising the binder and/or a structure-forming substance in no more than 1 wt. %.

14. The tablet of claim 1 , wherein the binder and/or a structure-forming substance is selected from the group consisting of polyvinylpyrrolidone, starch, lactose, calcium sulfate, mannitol, calcium phosphate, and a mixture of two or more of any of these.

15. The tablet of claim 1 , comprising no microcrystalline cellulose.

16. The tablet of claim 1 , comprising the eicosapentaenoic acid and the docosahexaenoic acid in the tablet, together, in 41 wt. % or more, based on the total tablet weight and measured in free acid form.

17. The tablet of claim 1 , comprising the eicosapentaenoic acid and the docosahexaenoic acid in the tablet, together, in 56.1 wt. % or more, based on the total tablet weight and measured in free acid form.

18. The tablet of claim 1 , comprising only the eicosapentaenoic acid and docosahexaenoic acid as omega-3 fatty acids.

19. A tablet, comprising:

an EPA salt of a first basic amino acid and eicosapentaenoic acid;

a DHA salt of a basic amino acid and docosahexaenoic acid; and optionally

a total amount of no more 10 wt. %, based on a total tablet weight, of a binder and/or a structure-forming substance selected from the group consisting of polyvinylpyrrolidone, starch, lactose, microcrystalline cellulose, calcium sulfate, mannitol, calcium phosphate, and a mixture thereof,

wherein a sum of the eicosapentaenoic acid and the docosahexaenoic acid in the tablet is 41 wt. % or more, based on the total tablet weight and measured in free acid form,

wherein the first and second basic amino acid are selected from the group consisting of lysine, arginine, ornithine, and a mixture thereof,

wherein the EPA salt and DHA salt are present as a mixture in powder form.

20. The tablet of claim 19 , wherein the sum of the eicosapentaenoic acid and the docosahexaenoic acid in the tablet is 50 wt. % or more, based on the total tablet weight and measured in free acid form.

21. The tablet of claim 19 , wherein the EPA salt and the DHA salt are obtained by a process comprising:

(i) precipitating the EPA salt and the DHA salt from an aqueous or alcoholic aqueous solution; and/or,

(ii) spray-drying of an aqueous or alcoholic aqueous solution of the first and second basic amino acid, the eicosapentaenoic acid, and the docosahexaenoic acid to obtain the EPA salt and the DHA salt, and

compressing the EPA salt and the DHA salt to form the tablet.

22. A tablet, comprising:

a salt of eicosapentaenoic acid with a first basic amino acid;

a salt of docosahexaenoic acid with a second basic amino acid;

a total amount of 20 wt. % or less, based on a total tablet weight, of a binder and/or a structure-forming substance selected from the group consisting of polyvinylpyrrolidone, starch, lactose, microcrystalline cellulose, calcium sulfate, mannitol, calcium phosphate, and a mixture thereof,

wherein a sum of the eicosapentaenoic acid and the docosahexaenoic acid in the tablet is 40 wt. % or more, based on the total tablet weight as free acids, and

wherein the eicosapentaenoic acid salt and the docosahexaenoic acid salt are in non-waxy solid form.

23. The tablet of claim 22 , wherein the omega-3 fatty acids are suitable to be compacted with a tablet press into the tablet without the binder and/or the structure-forming substance.